JP2007513872A5 - - Google Patents

Download PDF

Info

Publication number
JP2007513872A5
JP2007513872A5 JP2006536096A JP2006536096A JP2007513872A5 JP 2007513872 A5 JP2007513872 A5 JP 2007513872A5 JP 2006536096 A JP2006536096 A JP 2006536096A JP 2006536096 A JP2006536096 A JP 2006536096A JP 2007513872 A5 JP2007513872 A5 JP 2007513872A5
Authority
JP
Japan
Prior art keywords
group
alkyl
compound
substituted
branched
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006536096A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007513872A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2004/052639 external-priority patent/WO2005039550A2/en
Publication of JP2007513872A publication Critical patent/JP2007513872A/ja
Publication of JP2007513872A5 publication Critical patent/JP2007513872A5/ja
Withdrawn legal-status Critical Current

Links

JP2006536096A 2003-10-24 2004-10-22 Cb1拮抗作用を示す化合物の新規の医学的用途および前記化合物を伴う組み合わせ治療 Withdrawn JP2007513872A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03103961 2003-10-24
EP03103967 2003-10-27
PCT/EP2004/052639 WO2005039550A2 (en) 2003-10-24 2004-10-22 Novel medical uses of compounds showing cb1-antagonistic activity and combination treatment involving said compounds

Publications (2)

Publication Number Publication Date
JP2007513872A JP2007513872A (ja) 2007-05-31
JP2007513872A5 true JP2007513872A5 (cg-RX-API-DMAC7.html) 2007-09-13

Family

ID=34524748

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006536096A Withdrawn JP2007513872A (ja) 2003-10-24 2004-10-22 Cb1拮抗作用を示す化合物の新規の医学的用途および前記化合物を伴う組み合わせ治療

Country Status (8)

Country Link
EP (1) EP1753413A2 (cg-RX-API-DMAC7.html)
JP (1) JP2007513872A (cg-RX-API-DMAC7.html)
AU (1) AU2004283056A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0415851A (cg-RX-API-DMAC7.html)
CA (1) CA2543338A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA06004434A (cg-RX-API-DMAC7.html)
RU (1) RU2006117627A (cg-RX-API-DMAC7.html)
WO (1) WO2005039550A2 (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004058145A2 (en) 2002-12-19 2004-07-15 Merck & Co., Inc. Substituted amides
AR046132A1 (es) * 2003-10-24 2005-11-23 Solvay Pharm Gmbh Composicin farmaceutica que contiene al menos un compuesto con actividad de receptor de cb1, o un profarmaco , tautomero o sal del mismo, como componente activo adecuado para el tratamiento y/o profilaxis de enfermedades relacionadas con el receptor cb1 en pacientes juveniles y/o para el tratamiento
US7951805B2 (en) 2004-09-20 2011-05-31 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
EP1804799B1 (en) 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2289510A1 (en) 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
CA2580856A1 (en) 2004-09-20 2006-03-30 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
EP2316458A1 (en) 2004-09-20 2011-05-04 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
EP1799667B1 (en) 2004-09-20 2013-03-20 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as therapeutic agents
US7767677B2 (en) 2004-09-20 2010-08-03 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
EP2029138A1 (en) 2005-06-03 2009-03-04 Xenon Pharmaceuticals Inc. Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
EP1921073A1 (en) 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors
WO2024154047A1 (en) * 2023-01-18 2024-07-25 Brien Holden Vision Institute Limited Compositions and/or methods for prevention and/or treatment of dry eye disorders

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3003148B2 (ja) * 1989-01-05 2000-01-24 藤沢薬品工業株式会社 チアゾール化合物、その製造法およびそれを含有する医薬組成物
JPH10504542A (ja) * 1994-07-27 1998-05-06 ジー.ディー.サール アンド カンパニー 炎症処置用の置換チアゾール化合物
US5616601A (en) * 1994-07-28 1997-04-01 Gd Searle & Co 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
US6492516B1 (en) * 1999-05-14 2002-12-10 Merck & Co., Inc. Compounds having cytokine inhibitory activity
CZ2003698A3 (cs) * 2001-03-22 2003-06-18 Solvay Pharmaceuticals B. V. 4,5-Dihydro-1H-pyrazolové deriváty mající CB1-antagonistickou účinnost
TWI231757B (en) * 2001-09-21 2005-05-01 Solvay Pharm Bv 1H-Imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity
KR100950430B1 (ko) * 2001-09-21 2010-04-02 솔베이 파마슈티칼스 비. 브이 효력있는 cb1-길항 작용을 가지는4,5-디하이드로-1h-피라졸 유도체
CN101659639A (zh) * 2001-09-21 2010-03-03 索尔瓦药物有限公司 具有cb1-拮抗活性的新的4,5-二氢-1h-吡唑衍生物
PE20030547A1 (es) * 2001-09-24 2003-08-18 Bayer Corp Derivados de imidazol para el tratamiento de la obesidad
JP2005510508A (ja) * 2001-11-08 2005-04-21 藤沢薬品工業株式会社 アデノシンアンタゴニストとしてのチアゾールピリダジノン類
TW200407110A (en) * 2001-11-23 2004-05-16 Astrazeneca Ab New use for the treatment of gastroesophageal reflux disease
AU2003209388A1 (en) * 2002-01-29 2003-09-02 Merck And Co., Inc. Substituted imidazoles as cannabinoid receptor modulators
AR038966A1 (es) * 2002-03-18 2005-02-02 Solvay Pharm Bv Derivados de tiazol que tienen actividad antagonista, agonista o agonista parcial de cb1
TW200412942A (en) * 2002-08-06 2004-08-01 Abbott Lab Appetite control method
HRP20050053A2 (en) * 2002-09-19 2005-04-30 Solvay Pharmaceuticals B.V. 1 h-1,2,4-triazole-3-carboxamide derivatives as cannabinoid-cb1 receptor ligands
GB0230087D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents

Similar Documents

Publication Publication Date Title
CN112601750B (zh) Ptpn11(shp2)抑制剂
JP4890723B2 (ja) TNFαインヒビターとして有用なクマリン誘導体
RU2006101452A (ru) Пиридазинил-пиперазины и их применение в качестве лигандов h3 гистаминового рецептора
RU2004111979A (ru) Производные 1н-имидазола, обладающие св1-агонистической, частичной св1-агонистической или св1-антагонистической активностью
RU2006131132A (ru) 1,3,5,-тризамещенные производные 4,5-дигидро-1н-пиразола, обладающие св1-антагонистической активностью
JP2017531679A (ja) キナーゼ阻害剤として有用なインドールカルボキシアミド
RU2003130268A (ru) Производные 4,5-дигидро-1h-пиразола, обладающие сильной cb1-антагонистической активностью
RU2004114263A (ru) Производные тиазола, имеющие антагонистичекую агонистическую или частично агонистическую св1-активность
CN104892502A (zh) 作为醛固酮合酶抑制剂的芳基吡啶
JP6380777B2 (ja) PI3K、mTOR阻害薬としての縮合キノリン化合物
JP2020516591A (ja) Morアゴニストおよびkorアゴニストを含有する医薬組成物、およびその用途
CA2456606A1 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
MX2010006182A (es) Derivados de isoxazolo-piridazina.
JP2010510987A5 (cg-RX-API-DMAC7.html)
US12391664B2 (en) GluN2C/D subunit selective antagonists of the N-methyl-D-aspartate receptor
JP2016525104A5 (cg-RX-API-DMAC7.html)
JP2022511477A5 (cg-RX-API-DMAC7.html)
CA3178372A1 (en) Enpp1 modulators and uses thereof
RU2006117627A (ru) Новые применения в медицине соединений, обладающих антагонистической активностью по отношению к св1, и комбинированное лечение с применением этих соединений
JP2004507527A5 (cg-RX-API-DMAC7.html)
TW200927127A (en) Agent for overcoming resistance to anti-cancer agent
RU2007116987A (ru) Новые соединения
JP2006500315A (ja) 糖尿病状態に用いるヒスタミン−3受容体リガンド
JP2022514685A (ja) ペンタミジンの類似体及びその使用
EP1623741A2 (en) Cannabinoid receptor ligands for hair growth modulation